Search

Author/Creator Herrlinger, U

1. P01.012 Tumor Treating Fields (TTFields) in combination with lomustine (CCNU) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM). (19th September 2018)

Authors:
Lazaridis, L; Schäfer, N; Kebir, S; Weller, J; Tzaridis, T; Scheffler, B; Pierscianek, D; Kleinschnitz, C; Stuschke, M; Sure, U; Herrlinger, U; Glas, M
Journal:
Neuro-oncology
Issue:
Volume 20(2018)Supplement 3
Page Start:
iii230
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. P01.060 PriCoTTF: a phase I/II trial of Tumor Treating Fields prior and concomitant to radiotherapy in newly diagnosed glioblastoma. (19th September 2018)

Authors:
Glas, M; Scheffler, B; Lazaridis, L; Herrlinger, U; Pierscianek, D; Sure, U; Pröscholdt, M; Hau, P; Hense, J; Kleinschnitz, C; Grosu, A; Stuschke, M; Kebir, S
Journal:
Neuro-oncology
Issue:
Volume 20(2018)Supplement 3
Page Start:
iii243
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. OS2.1 Objective responses to chemotherapy in recurrent glioma do not predict better survival: A prospective analysis from the German Glioma Network. (19th September 2018)

Authors:
Bähr, O; Hentschel, B; Hattingen, E; Reusche, M; Tatagiba, M; Tonn, J; Schnell, O; Schackert, G; Westphal, M; Herrlinger, U; Pietsch, T; Reifenberger, G; Weller, M; Löffler, M; Steinbach, J P
Journal:
Neuro-oncology
Issue:
Volume 20(2018)Supplement 3
Page Start:
iii218
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. P01.013 Long-term analyses of the NOA-08 randomized phase III trial of temozolomide versus radiotherapy for elderly patients with malignant astrocytomas. (19th September 2018)

Authors:
Wick, A; Kessler, T; Platten, M; Meisner, C; Bamberg, M; Herrlinger, U; Felsberg, J; Weyerbrock, A; Seidel, C; Steinbach, J P; Sabel, M; Vesper, J; Debus, J; Sahm, F; Meixensberger, J; Ketter, R; Mayer-Steinacker, R; von Deimling, A; Reifenberger, G; Weller, M
Journal:
Neuro-oncology
Issue:
Volume 20(2018)Supplement 3
Page Start:
iii230
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. P01.013 Long-term analyses of the NOA-08 randomized phase III trial of temozolomide versus radiotherapy for elderly patients with malignant astrocytomas. (19th September 2018)

Authors:
Wick, A; Kessler, T; Platten, M; Meisner, C; Bamberg, M; Herrlinger, U; Felsberg, J; Weyerbrock, A; Seidel, C; Steinbach, J P; Sabel, M; Vesper, J; Debus, J; Sahm, F; Meixensberger, J; Ketter, R; Mayer-Steinacker, R; von Deimling, A; Reifenberger, G; Weller, M
Journal:
Neuro-oncology
Issue:
Volume 20(2018)Supplement 3
Page Start:
iii230
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. PL03.4.A Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period. (9th September 2021)

Authors:
Coomans, M; Dirven, L; Aaronson, N; Baumert, B; van den Bent, M; Bottomley, A; Brandes, A; Chinot, O; Coens, C; Gorlia, T; Herrlinger, U; Keime-Guibert, F; Malmström, A; Martinelli, F; Stupp, R; Talacchi, A; Wick, W; Reijneveld, J; Taphoorn, M
Journal:
Neuro-oncology
Issue:
Volume 23: Supplement 2(2021)
Page Start:
ii2
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. P11.15.B First multicentric real-life experience with the combination of lomustine and temozolomide in newly diagnosedMGMT promoter methylatedIDH wildtype glioblastoma. (5th September 2022)

Authors:
Lazaridis, L; Schmidt, T; Agkatsev, S; Blau, T; Spille, D; Heider, S; Schulz, T; Bumes, E; Oster, C; Feldheim, J; Stummer, W; Kessler, A; Seidel, C; Hau, P; Sure, U; Keyvani, K; Herrlinger, U; Kleinschnitz, C; Stuschke, M; Herrmann, K
Journal:
Neuro-oncology
Issue:
Volume 24(2022)Supplement 2
Page Start:
ii58
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. OS7.4 Calculating the net clinical benefit in brain tumor clinical trials by combining survival and health-related quality of life data using two methods: quality adjusted survival effect sizes (QASES) and joint modelling (JM). (6th September 2019)

Authors:
Coomans, M; Dirven, L; Bottomley, A; van den Bent, M; Sloan, J; Stupp, R; Weller, M; Reijneveld, J C; Taphoorn, M; Aaronson, N; Baumert, B G; Brandes, A A; Chinot, O; Coens, C; Gorlia, T; Herrlinger, U; Keime-Guibert, F; Malmström, A; Martinelli, F; Talacchi, A
Journal:
Neuro-oncology
Issue:
Volume 21(2019)Supplement 3
Page Start:
iii14
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗